| May 30 |
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
|
| May 30 |
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
|
| May 16 |
Galapagos creates new subscription right plans
|
| May 15 |
Galapagos, BCA to collaborate on CAR-T cell therapy production
|
| May 15 |
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
|
| May 6 |
Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript
|
| May 4 |
Galapagos NV (GLPG) Q1 2024 Earnings Call Transcript
|
| May 4 |
Galapagos First Quarter 2024 Earnings: EPS: €0.36 (vs €0.35 in 1Q 2023)
|
| May 2 |
Galapagos reports Q1 results
|
| May 2 |
Galapagos reports first quarter 2024 financial results
|
